Glycosylated antibody

Abstract

The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.

1 . A method of treating a human patient suffering from a disease or disorder responsive to treatment with a therapeutic antibody, which comprises 
 repeated administration of a therapeutically effective amount of a human or humanized antibody expressed and glycosylated in a CHO cell expression system, to a patient in need thereof.    
     
     
         2 . The method of  claim 1 , wherein said disease or disorder is selected from the group consisting of T-cell mediated disorders, autoimmune disorders, cancer and infections diseases.  
     
     
         3 . The method of  claim 2 , wherein said T-cell mediated disease is selected from the group consisting of severe vasculitis, rheumatoid arthritis and systemic lupus.  
     
     
         4 . The method of  claim 2 , wherein said autoimmune disorder is selected from the group consisting of multiple sclerosis, graft versus host disease, psoriarsis, juvenile onset diabetes, Sjogrens' disease, thyroid disease, myasthenia gravis, transplant rejection and asthma.  
     
     
         5 . The method of  claim 2 , wherein said cancer is non-Hodgkin's lymphoma or multiple myeloma.  
     
     
         6 . The method of  claim 2 , wherein said infectious disease is HIV or herpes.  
     
     
         7 . The method of  claim 1 , wherein the antibody is administered daily for up to 30 days.  
     
     
         8 . The method of  claim 7 , wherein the dose of antibody is between 1 to 100 mg.  
     
     
         9 . A method of treating a human patient suffering from a disease or disorder responsive to treatment with a therapeutic antibody, which comprises 
 administering a therapeutically effective amount of a human or humanized antibody expressed and glycosylated in a CHO cell expression system, to a patient in need thereof, in a two-part dosing regime, wherein the antibody is administered in different doses in each part of the two-part dosing regime.    
     
     
         10 . The method of  claim 9 , wherein the two-part dosing regime comprises a first dosing regime, in which the antibody is administered at a dose of 1 to 5 mg for 5-10 days and a second part, in which the antibody is administered at 6-15 mg for an additional 5-10 days.